GlaxoSmithKline epilepsy drug Lamictal approved for new indication

By Elaine Rigoli

Tampa, Fla., Sept. 25 - The Food and Drug Administration approved a new use of GlaxoSmithKline's anti-seizure medicine Lamictal (lamotrigine) tablets for the treatment of one of the most serious forms of epilepsy - primary generalized tonic-clonic seizures, also known as grand mal seizures.

With this new indication, Lamictal can now be used as add-on therapy to treat primary generalized tonic-clonic seizures in children aged two and older as well as adults.

The London pharmaceutical company also said this new use marks the fifth FDA approval for Lamictal in epilepsy, making it one of the few antiepileptic drugs with established efficacy in a broad spectrum of seizure types, including partial and generalized seizures.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.